MedPath

Effect of edaravone against consciousness impairment after encephalitis

Phase 2
Conditions
imbic encephalitis
Registration Number
JPRN-UMIN000010052
Lead Sponsor
niversity of Tsukuba
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

1.male:Cre<1.3 mg/dl Female:Cre<1.0 mg/dl male & femaile:AST/ALT<more than three times the reference value 2.sepsis 3.epilepticus and severe coma 4.bacterial meningitis and encephalitis 5.DIC 6.allergy for edaravone 7. edaravone is used within two weeks prior to registration 8.acute cereberal infarction 9.Patients within 6 months after the end of the other trial 10.investigator has determined the patient disqualified as a target

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath